However, treatment goals must remain clear
Most protocols begin at 1 to 2 mg, which produces modest glucagon receptor activation
74 For instance, in the Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients (STEP) trial, weekly semaglutide administration resulted in a mean body weight reduction of 14.9% from baseline among overweight or obese non-diabetic individuals, 76 a magnitude of weight loss previously observed only following bariatric surgery
To put that in perspective, the approved GLP-1 drugs achieved less weight loss in longer timeframes: for example, semaglutide (Wegovy) averages about 15% weight loss over ~16 months, and tirzepatide (Zepbound) achieved around 22.5% at 72 weeks in trials
Additionally, they suggest selectively preventing oxidative stress in aquaculture animals, clarifying the mechanism of selenoproteins in the antioxidant system of aquatic animals, and providing guidance for studying selenium toxicity